The Dedham Group, LLC

The Dedham Group, LLC offers strategic consulting services with a specialization in the life sciences sector, particularly in healthcare and biopharmaceuticals, focusing on enhancing patient access to innovative therapies and optimizing market strategies for clients. Founded in 2010 and headquartered in New York, US, The Dedham Group, LLC provides strategy consulting primarily in the life sciences sector. The firm was acquired on April 15, 2021, by Managed Markets Insight & Technology, LLC, a portfolio company of Welsh, Carson, Anderson & Stowe. The firm's founder, Robert Hung, has a history of involvement in the consulting industry, although details of other ventures are not specified.

The Dedham Group provides comprehensive strategy consulting services primarily focused on the life sciences sector, especially in healthcare and biopharmaceuticals. Their core offerings encompass market access strategies, clinical pathways development, and patient support programs designed to enhance patient access to innovative therapies. Additionally, they specialize in distribution strategy, payer access, and reimbursement consulting, aiming to dismantle barriers affecting payer, provider, and patient interactions. The firm’s expertise extends across various therapeutic categories, including oncology, immunology, and rare diseases, providing strategic direction to clients such as biopharma companies and healthcare providers primarily in North America and Europe.

Their clientele consists of both large pharmaceutical entities and emerging biotech firms seeking to optimize their market positioning and access strategies. Revenue generation for The Dedham Group is derived from consulting engagements structured around tailored service agreements. These transactions typically involve B2B agreements where clients engage the firm for strategic advisory services, often on a project basis or through longer-term contracts that encompass multiple consulting areas. The firm’s pricing model is reflective of the specialized nature of its services, with fees structured based on the scope of projects, complexity, and the specific expertise required.

While specific pricing details for services are not disclosed, engagements may involve a combination of fixed fees for defined projects and hourly consulting rates for ongoing advisory support. The firm’s flagship offerings, including their value and access strategy services, are central to their revenue model as they address critical industry demands in advancing therapeutic access and commercialization. The Dedham Group plans to leverage its recent acquisition to expand its offerings in the life sciences consulting space. Following the acquisition on April 15, 2021, the firm aims to enhance its service portfolio and expand into new geographic markets within Europe and Asia by 2023.

The funds from the acquisition will support the development of new products designed to improve market access strategies and patient support programs. This strategic focus aims to position The Dedham Group as a key player in addressing the evolving needs of the biopharmaceutical industry.